Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue 2, 2004, Pages 107-117

  Meininger, Vincent ^a   Bensimon, Gilbert ^a   Bradley, Walter G ^b   Brooks, Benjamin R ^c   Douillet, Patrice ^d   Eisen, Andrew A ^e   Lacomblez, Lucette ^a   Leigh, P Nigel ^f   Robberecht, Wim ^g  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of Wisconsin Health   (United States)

^d SANOFI   (France)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; GABAPENTIN; GLUCOSE; PLACEBO; RECOMBINANT SOMATOMEDIN C; RILUZOLE; XALIPRODEN; NAPHTHALENE DERIVATIVE; PYRIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASSISTED VENTILATION; ASTHENIA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GASTROSTOMY; HUMAN; HYPERGLYCEMIA; HYPESTHESIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR NEURON DISEASE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NONBIOLOGICAL MODEL; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TIME; TINNITUS; TRACHEOSTOMY; TREATMENT OUTCOME; VERTIGO; VITAL CAPACITY; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PYRIDINES;

EID: 3843136368     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/14660820410019602     Document Type: Article

References (24)

1. Leigh PN. Pathogenic mechanisms in amyotrophic lateral sclerosis and other motor neuron disordersIn: Calne DB, ed. Neurodegenerative Diseases. Philadelphia, PA: WB Saunders and Co. 1994: 473-488.
2. Swash M, Schwartz MS. Motor neuron disease: the clinical syndrome. In: Leigh PN, Swash M, eds. Motor Neuron Disease: Biology and ManagementLondon: Springer Verlag 1995: 1-17.
3. Tysnes OB, Vollet SE, Larsen TP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosisNeuroepidemiol 1994; 13: 226-235.
4. Lacomblez L, Bensimon C, Leigh PN, Guillet P. Meininger V for the Amyotrophic lateral sclerosis/riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosisLancet 1996; 347: 1425-1431.
5. Bensimon C, Lacomblez L, Meininger V, and the ALS/riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosisN Engl J Med 1994; 330: 585-591.
6. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review)In: The Cochrane Library, Issue 3. Oxford: Update Software (2002).
7. Fournier J, Keane PE, Ferrara P, Soubrié P. SR57746A: An orally active non-peptide compound with neuroprotective and neurotrophic effectsCNS Drug Reviews 1997; 3:148-167.
8. Labie C, Lafon C, Marmouget C et al. Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortexBr J Pharmacol 1999; 127: 139-144.
9. Duong F, Fournier J, Keane PE et al. The effect of the nonpeptide neurotrophic compound SR57746A on the progression of the disease state of the pmn mouseBr J Pharmacol 1998; 124: 811-817.
10. Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V. Xaliproden in amyotrophic lateral sclerosis: overview about the early clinical development programme and main resultsAmyotroph Lateral Scler Other Motor Neuron Disord (accepted in ALS and other MND).
11. Airlie House World Federation of Neurology. Guidelines for ALS clinical trialsJ Neurol Sci 1995; 129: 1-10.
12. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS2nd Airlie House Workshop 1998 (available from http://wfnals.org).
13. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosisJ Neurol Sci 1994; 124 (suppl): 96-107.
14. European Coal and Steel Community, Quanjer PH. Working Party "Standardization of Lung Function Tests"In: Chapter 7: Summary equations of reference values. Bull Eur Physiopathol Respir 1983; 19 (suppl 5): 45-51.
15. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significanceBiometrika 1988; 75(4): 800-802.
16. Cox DR. Regression models and life-tablesJ R Stat Soc [B] 1972; 34: 187-220.
17. O'Brien PC. Procedures for comparing samples with multiple endpointsBiometrics 1984; 40: 1079-1084.
18. Committee for Proprietary Medicinal Products (CPMP). Points to consider on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS)EMEA 2000, Oct. 19, London: 1-4.
19. Miller RG, Rosenberg JA, Gelinas D et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review)Neurology 1999; 52: 1311-1323.
20. Goldblatt D, Greenlaw J. Starting and stopping the ventilator for patients with amyotrophic lateral sclerosisNeurol Clin 1989; 7(4): 789-806.
21. Sanjak M, Salachas F, Frija-Orvoen F et al. Prospective quality control of vital capacity (VC) as primary endpoint in international multi-centre therapeutic trial of SR57746A (xaliproden) in amyotrophic lateral sclerosis (ALS)Amyotr Lat Scler 2000; 1(supp 3): 59-60.
22. Meininger V, Bensimon C, Lacomblez L, Salachas F. Natural history of amyotrophic lateral sclerosisIn: Serratrice G and Munsat T, eds. Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis, Advances in Neurology, vol.28. Philadelphia: Lippincott-Raven Publishers, 1995: 199-207.
23. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study GroupNeurology 1998; 50(1): 66-72.
24. Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs. sleep-disordered breathing as predictors of QOL in ALSNeurology 2001; 57: 2040-2044.